Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Familial Hypercholesterolaemia in the Asia-Pacific Region
Author(s): Satoshi Honda , Jonathan Yap , Ivan Olegario , et al Added: 4 months ago

Prevention & Chronic Conditions
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Renal Metabolic
ESC 23: LIBerate-HeFH Study
Author(s): Frederick Raal Added: 2 years ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104). The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in… View more

Inherited and Congenital Cardiac Conditions

Prevention & Chronic Conditions
AHA 24: The LIBerate-HeFH_OLE Study
Author(s): Frederick Raal Added: 1 year ago
AHA Conference 2024 - Long-term safety and efficacy outcomes of lerodalcibep, a third generation PCSK9 inhibitor (LIB Therapeutics LLC), in heterozygous familial hypercholesterolemia (HoFH) subjects.Prof Frederick Raal (University of the Witwatersrand, ZA) joins us onsite at AHA Conference to discuss the findings from LIBerate-HeFH_OLE (NCT04798430; LIB Therapeutics).LIBerate-HeFH_OLE is an open… View more

Prevention & Chronic Conditions
Erik Stroes
Job title: Chairman of the lipid clinic
Prof Erik Stroes is Chairman of the lipid clinic at Amsterdam University Medical Center (UMC) in the Netherlands. Prof Stroes is a vascular internist with a longstanding track of research in the field of lipidology, inflammation and atherosclerosis. His current research foci encompass the use of CT-angiography as a guide to tailored treatment regimens, pathophysiology of Lp(a) in atherogenesis… View more
Job title: Founder of the Lipid Research Clinic
Author(s): Stephen Nicholls Added: 5 months ago
ESC Congress 2025 - Pooled MACE Analysis of obicetrapib shows reductions in cardiovascular events and consistent reductions in LDL cholesterol and LP(a).Prof Stephen Nicholls (Monash Victorian Heart Institute, AU) joins us to discuss findings from a pooled major adverse cardiovascular events (MACE) analysis of obicetrapib, examining early signals of cardiovascular benefit in patients with… View more

Prevention & Chronic Conditions
Frederick Raal
Research Area(s) / Expertise: Job title: Professor and Director of the Carbohydrate and Lipid Metabolism Research Unit
Professor Frederick Raal is a distinguished Professor and the Director of the Carbohydrate and Lipid Metabolism Research Unit at the University of the Witwatersrand in Johannesburg, South Africa. He also serves as the Head of the Division of Endocrinology and Metabolism at the same institution.He graduated with an MBBCh degree in 1981, followed by a Master of Medicine in 1991, a PhD in 2000, and… View more
AHA 24: The BROOKLYN Study
Author(s): Stephen Nicholls Added: 1 year ago
AHA Conference 2024 - BROOKLYN: Safety and efficacy outcomes of obicetrapib (NewAmsterdam Pharma) alongside lipid-lowering therapy in Heterozygous Familial Hypercholesterolemia (HeFH) management.Dr Stephen Nicholls (Monash University and The Victorian Heart Hospital, Melbourne, AU) joins us onsite at AHA Conference to discuss the findings from BROOKLYN (NCT05425745).BROOKLYN is a phase 3,… View more

Prevention & Chronic Conditions